Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

Home

/

NVAX

N

Novavax, Inc. (NVAX)

NMS – Цена в реальном времени. Валюта: USD

9.62

+0.12 (1.26%)

При закрытии: May 12, 2026, 4:00 PM EDT

9.67

+0.05 (0.52%)

До открытия: May 13, 2026, 4:44 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday's close of $54.35.

Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb

Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb

Moderna Inc. (NASDAQ:MRNA) and Novavax Inc. (NASDAQ:NVAX) shares moved higher Monday as traders piled back into vaccine names following renewed concerns over a hantavirus outbreak tied to the MV Hondius cruise ship.

Hantavirus cases spark surge in pharma and biotech stocks — here's why

Hantavirus cases spark surge in pharma and biotech stocks — here's why

Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.

What's Going On With Novavax Stock On Friday?

What's Going On With Novavax Stock On Friday?

Novavax Inc. (NASDAQ:NVAX) stock is trading higher on Friday in reaction to a surge in Moderna Inc. (NASDAQ:MRNA).

Novavax to Participate in BofA Securities 2026 Health Care Conference

Novavax to Participate in BofA Securities 2026 Health Care Conference

GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.

NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum

NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

Видео

No Data

There is no data to display

Пресс-релизы

Novavax to Participate in BofA Securities 2026 Health Care Conference

Novavax to Participate in BofA Securities 2026 Health Care Conference

GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.

Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

06.05.2026

Novavax Reports First Quarter 2026 Financial Results and Operational Highlights

Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M ® in two infectious disease areas In April, Novavax signed a new MTA with a top 10 leading pharmaceutical company and leader in oncology to explore Matrix-M in multiple oncology and infectious disease targets In April, Novavax expanded an existing partnership with a new MTA, providing access to Matrix-M for exploration in up to nine additional identified infectious diseases In February, Novavax expanded an existing MTA with a major global pharmaceutical company to explore an additional field and signed a new MTA with an oncology company Sanofi announced positive results from the Phase 4 COMPARE study, a head-to-head study comparing Nuvaxovid™ and Moderna's mNEXSPIKE that reinforces Nuvaxovid's well established and differentiated reactogenicity profile Novavax's C. difficile vaccine candidate prioritized with potential to enter the clinic as early as 2027 Reiterates 2026 Revenue Framework and Combined R&D and SG&A expense guidance GAITHERSBURG, Md.

Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development

Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D).

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025 Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025 Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027 Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&D and SG&A expense reduction goals and is improving future targets GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.